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Estrogen is a female sex steroid hormone that plays a significant role in physiological functions. Evidence suggests
that estrogen-signaling pathways are closely linked to cancer development and progression. The novel G protein-
coupled estrogen receptor (GPER or GPR30) has been shown to influence cancer predisposition and progression,
although results of related studies remain equivocal. Thus, this meta-analysis aimed to estimate the relationship
between GPER gene polymorphisms and GPER expression levels, with cancer predisposition and progression. The
pooled results showed that two GPER polymorphisms, rs3808350 and rs3808351, were significantly associated
with cancer predisposition, especially in the Asian population, but no significant association was detected for
rs11544331. In parallel, we also found that cancer aggressiveness and progression correlated with rs3808351 and
GPER expression in cancerous tissues. Altogether, our findings suggest that GPER plays a pivotal role in cancer
pathogenesis and progression. We suggest that rs3808350 and rs3808351 may be used as a prospective biomarker
for cancer screening; while rs3808351 and GPER expression can be used to examine the prognosis of patients with
cancer. Further biological studies are warranted to confirm our findings.1. Introduction
Estradiol (E2) is a major form of estrogen and displays pleiotropic
steroid function that play regulatory roles in many physiological pro-
cesses [1, 2]. Biosynthesis of E2 is determined by the conversion of
testosterone by a rate-limiting enzyme, aromatase (CYP19A1) [1, 2, 3, 4,
5, 6]. E2-mediated effects are modulated through both genomic and
non-genomic pathways by the nuclear and membrane estrogen receptor
(ER), respectively [2]. Recent reports have suggested a pivotal role of E2
in both the development and malignant progression of multiple cancers
[7]. Several meta-analysis have demonstrated that cancer risk is associ-
ated with the polymorphism of ER-alpha (ERα) [8], but not ER-beta (ERβ)
[9]. However, the role of membrane ERs, such as the G protein-coupled
estrogen receptor (GPER), with cancer pathogenesis remains elusive.
GPER has been identified as a novel ER, and is a seven-
transmembrane domain protein that is structurally distinguished from
the classical ERα and ERβ [10]. GPER mediates rapid E2-induced non-
genomic signaling events, resulting in long-term transcriptional changes
and a broad range of response among a large variety of cell types [10,ac.id (Z.S. Ulhaq).
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evier Ltd. This is an open access a11]. Such evidence was supported by the expression of GPER in various
human tissues, including lung, heart, brain, liver, skeletal muscle, and
lymphoid tissues [12]. Additionally, E2 exerts ten times higher binding
capacity to GPER than ERα [13], implying a critical role of GPER in
regulating normal physiological functions.
GPER overexpression has been reported in several hormone-
dependent malignancies, including cancers of the breast, ovaries, and
endometrium [10]. The upregulation of GPER is also evident in semi-
noma and lung cancer [10, 14]. Additionally, GPER overexpression has
also been associated with poor treatment outcomes such as lowered ef-
ficacy of primary endocrine treatment in breast cancer patients [15] and
poor-prognosis of endometrial cancers, uterine carcinosarcoma, and
endometriosis [16]. The finding indicates that GPER expressed in
ERα/β-negative breast cancer could induce the expression of connective
tissue growth factor (CTGF) [17], and thus binding of E2 to GPER for cell
proliferation and migration. Hence, several studies have been proposed
to identify novel GPER ligands with specific antiproliferative effects
against estrogen-based malignancies [18, 19].2 March 2021
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genomic sequence that could potentially result in modifications of gene
expression level as well as protein structure, level, and function [17]. The
expression level of GPER mRNA is possibly affected by its polymorphism
[20]. Although several SNPs have been identified in the GPER gene, only
three were reported to have higher biological relevance with human
neoplasms, which are rs3808350, rs3808351, and rs11544331 [10].
However, the role of GPER polymorphism in cancer remains inconclusive
as shown by different results in various studies [10, 13, 16, 17]. There-
fore, this meta-analysis was conducted in order to understand the role of
GPER with cancer predisposition and progression.
2. Methods
2.1. Literature search and data extraction
A meta-analysis was performed according to the Preferred Report-
ing Items for Systematic Reviews and Meta-Analysis (PRISMA) guide-
lines [21]. A literature search was conducted in MEDLINE and EMBASE
using keywords such as “GPER/GPR30”, “polymorphisms”, “immuno-
histochemistry”, “expression/level”, and “cancer”, singularly and in
combination. The literature search was updated until July, 2020. The
inclusion criteria of studies were as follows: (1) evaluating the asso-
ciation between GPER rs3808350, rs11544331, and rs3808351 poly-
morphisms and cancer predisposition, (2) conducted with a
case-control design, and (3) evaluating GPER expression level
(immunohistochemistry) and cancer progression. Data were extracted
as follows: (1) name of the first author, (2) year of publication, (3) type
of cancer, (4) the number of cases and controls, (5) number of geno-
types in cases and controls, (6) number of haplotypes of
rs3808350/rs3808351/rs11544331 in cases and controls, and (7)
number of patients with GPERþ/– or high/low.2.2. Statistical analysis
Meta-analysis for each gene polymorphism was performed for two
or more studies, as previously described [3, 4, 5, 6, 22, 23, 24, 25].
Genotypic frequency of GPER gene polymorphism was tested for de-
viation from the Hardy–Weinberg equilibrium (HWE) in the control
subjects if HWE was not reported. The genetic association was exam-
ined using different genetic models, including allelic (a vs. A), reces-
sive (aa vs. AaþAA), dominant (aaþ Aa vs. AA), over dominant (Aa vs.
aa þ AA), homozygous (aa vs. AA), and heterozygous (Aa vs. AA)
models [5, 22, 23, 24, 25, 26, 27, 28, 29, 30]. The associations between
GPER gene polymorphisms or GPER expression levels with cancer
predisposition and progression were calculated by the pooled odds
ratio (OR) and 95% confidence interval (CI). Heterogeneity among
studies was evaluated using Q test and I2 statistic. A significant
Q-statistic (p < 0.10) indicated heterogeneity across studies. The I2
values indicated no (0–24.9%), low (25–49.9%), moderate
(50–74.9%), or high (75–100%) heterogeneity. The random-effect
model (REM) was used if heterogeneity existed; otherwise, the
fixed-effect model (FEM) was used [31, 32, 33, 34, 35, 36, 37]. Sub-
group analysis was conducted by stratifying based on ethnicity, type of
cancer, and localization of GPER expression. In addition, we also
evaluated the association between rs3808351 and tumor size, as well
as the involvement of haplotypes rs3808350/rs3808351/rs11544331
with cancer predisposition. Potential publication bias was assessed by
Begg's funnel plots and Egger's regression test. Begg's funnel plot was
applied if the pooled effect size consisted of 10 or more studies. The
Newcastle Ottawa Scale (NOS) was adopted to assess the quality of the
case-control study, with a score of 8–9 for all included studies, indi-
cating a low risk of bias (Supplementary Table 1). A sensitivity analysis
was performed by sequentially omitting each study one at a time, and
the results remained unchanged (data not shown), implying the2
robustness and stability of the findings. A quantified result of p < 0.05
was indicative of statistical significance.
3. Results
3.1. Relationship between GPER gene polymorphisms and cancer
For GPER gene polymorphisms, a total of 142 articles were screened,
among which 11 were reviewed. Six studies were excluded due to not
relating to cancer or GPER rs3808350, rs11544331, and rs3808351
polymorphisms. Five studies were then included in this meta-analysis
[10, 13, 16, 17, 38]. From 5 studies, Chevalier et al. [10] and Giess
et al. [17] recruited testicular and breast cancer patients, respectively,
while Kasap et al. [16] and Hong et al. [13] enrolled patients with uterine
leiomyoma and adenomyosis/uterine leiomyoma/another precancerous
lesion of uterine-cervix, respectively. The last included study recruited
gynecomastia patients [38], and although it should be noted that some
reports have classified the condition as a non-malignant male breast
disorder [39], gynecomastia has shown strong association with GPER
[38], exhibiting a nearly 10-fold increased risk of breast cancer in men
[40]. A total of 1,288 (case: 601, control 687), 5,565 (case: 729, control:
4,836), and 1,294 (case: 610; control: 684) subjects for GPER rs3808350,
rs11544331, and rs3808351 polymorphisms, respectively, were further
analyzed. All studies complied with the HWE except for the study from
Chevalier et al. (for rs11544331 and rs3808351) [10]. Details of the
retrieved studies are shown in Table 1.
The pooled result of the analyses is shown in Table 2. Overall, there
was no significant association between GPER rs3808350, rs11544331,
and rs3808351 polymorphisms with cancer predisposition in all inheri-
tance models, even when the studies evaluating gynecomastia or/and
study deviated from HWE were excluded (Table 2). However, subgroup
analyses stratified by ethnicity revealed a significant association between
rs3808350 (G vs. A, OR ¼ 1.38, 95%CI ¼ 1.06–1.79, p ¼ 0.015; GG vs.
AG þ AA, OR ¼ 2.20, 95%CI ¼ 1.42–3.43, p ¼ 0.000 or OR ¼ 2.11, 95%
CI ¼ 1.19–3.74, p ¼ 0.010; GG vs. AA, OR ¼ 1.83, 95%CI ¼ 1.10–3.04, p
¼ 0.019; AG vs. AA, OR¼ 0.51, 95%¼ CI 0.28–0.95, p¼ 0.033; Table 2)
and rs3808351 (A vs. G, OR ¼ 0.51, 95%CI ¼ 0.34–0.75, p ¼ 0.000; AA
vs. GAþGG, OR¼ 0.34, 95%CI¼ 0.14–0.78, p¼ 0.011; AAþGA vs. GG,
OR¼ 0.48, 95%CI¼ 0.29–0.81, p¼ 0.006; AA vs. GG, OR¼ 0.28, 95%CI
¼ 0.11–0.69, p¼ 0.005; GA vs. GG, OR¼ 0.56, 95% ¼ CI 0.32–0.98, p¼
0.043; Table 2) with cancer predisposition. Ethnicity did not associate
with predisposition of cancer for rs11544331 (data not shown). In
addition, no association was also observed in any haplotypes of
rs3808350/rs3808351/rs11544331 with cancer predisposition
(Table 3).
In addition to the association of GPER polymorphism with cancer
predisposition, we also evaluated the association between rs3808351
and tumor size (Table 4). The analysis showed that rs3808351 (AA þ GA
vs. GG, OR¼ 0.46, 95%CI¼ 0.28–0.76, p¼ 0.002; GA vs. GG, OR¼ 0.46,
95% ¼ CI 0.27–0.79, p ¼ 0.004; Table 5) was associated with smaller
tumor size.
3.2. Relationship between GPER expression levels and cancer progression
A total of 204 articles were first screened to evaluate the association
between GPER expression levels with cancer progression. After review-
ing the title, abstract, and removing duplications, 151 articles were
excluded, and 53 articles were then further evaluated. Among them, 33
articles were subsequently removed either because the data cannot be
extracted, or the studies did not provide immunohistochemistry results.
Finally, 20 articles were included in this meta-analysis [41, 42, 43, 44,
45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60]. The
characteristics of the included studies are shown in Table 6.
The meta-analysis results regarding pooled GPER expression levels
and cancer progression are shown in Table 7. In brief, no associations
were found between GPER expression levels with tumor size, stage, nor
Table 1. Characteristics of individual studies for the association between GPER polymorphisms and cancer.
No Author (year) Disease Country/Ethnicity Sample size SNP Definition of allele *p HWE Genotype distribution
Case Control Ref. Alt. Case Control
AA Aa aa AA Aa aa
1 Korkmaz et al (2014) Gynecomastia Turkey/Asian 109 104 rs3808350 A G 0.5295 37 41 31 44 45 15
2 Chevalier et al (2014) Testicular cancer France/Caucasian 89 224 0.6146 45 41 3 82 110 32
3 Hong et al (2019) Adenomyosis Korea/Asian 35 34 0.2115 8 12 15 4 20 10
4 Giess et al (2010) Breast cancer Germany/Caucasian 257 247 0.4092 100 121 36 96 111 40
5 Kasap et al (2016) Uterine leiomyoma Turkey/Asian 111 78 0.8309 41 33 37 27 37 14
1 Korkmaz et al (2014) Gynecomastia Turkey/Asian 109 104 rs11544331 C T 0.0873 61 43 5 66 37 1
2 Chevalier et al (2014) Testicular cancer France/Caucasian 223 4,374 0.0005 78 43 2 2843 1321 210
3 Hong et al (2019) Adenomyosis Korea/Asian 35 34 1 33 2 0 34 0 0
4 Giess et al (2010) Breast cancer Germany/Caucasian 251 246 0.5145 146 88 18 128 96 22
5 Kasap et al (2016) Uterine leiomyoma Turkey/Asian 111 78 0.5106 44 45 22 23 36 19
1 Korkmaz et al (2014) Gynecomastia Turkey/Asian 109 104 rs3808351 G A 0.4980 36 46 27 52 41 11
2 Chevalier et al (2014) Testicular cancer France/Caucasian 100 222 0.0031 16 69 15 96 114 12
3 Hong et al (2019) Adenomyosis Korea/Asian 35 34 0.0989 27 7 1 19 15 0
4 Giess et al (2010) Breast cancer Germany/Caucasian 255 246 0.0545 133 99 23 130 89 27
5 Kasap et al (2016) Uterine leiomyoma Turkey/Asian 111 78 0.1432 57 45 9 28 32 18
Alt., alternative allele; Ref., reference allele; SNP, single nucleotide polymorphism; *p for Hardy–Weinberg equilibrium test in controls; A, Wild type; a, mutant type.
Bold values indicate statistically significant p < 0.05.
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formed, yielding similar findings, with the exception of a significant as-
sociation between GPER expression with higher tumor stage in the Asian
population (OR ¼ 2.22, 95% CI ¼ 1.12–4.41, p ¼ 0.022, Table 7). No
association was also observed when the analysis was performed based on
the localization of GPER (data now shown).
3.3. Publication biases
Publication biases were examined by Begg's funnel plots and Egger's
regression tests. Overall, funnel plots were symmetrical (data not shown)
and p-values of Egger's regression test greater than 0.05, suggesting that
publication biases did not likely influence the results.
4. Discussion
To date, this study is the first to summarize the association between
GPER gene polymorphisms and GPER expression levels with cancer. The
pooled meta-analyses results demonstrated that GPER rs3808350 and
rs3808351, but not rs11544331, were significantly associated with
cancer predisposition, specifically in the Asian population. Patients
harbouring the A allele of rs3808351 exhibited a lower risk of developing
cancer and displayed smaller tumor size. Moreover, GPER expression
levels in cancerous tissues were correlated with higher tumor stage in the
Asian population.
Our finding reinforces previous reports that A allele carriers of
rs3808350 and rs3808351 exhibit protective effects against uterine
leiomyoma and gynecomastia risks in the Turkish population [17, 38].
Similar to our findings, Giess et al. [17] observed that AA and AG ge-
notypes of rs3808351 were correlated with lower tumor stage and grade.
Although we did not observe a significant association between
rs11544331 and cancer risk, it has been suggested that rs11544331
(P16L) can alter the conformational structure and localization of GPER,
resulting in defective GPER function and the aggravated migration of
carcinoma cells [61]. We also found no significant relationship between
haplotypes of rs3808350/rs3808351/rs11544331 with cancer predis-
position, possibly because our analysis was pooled from two studies
reporting different cancer type/disease. Considering the potential func-
tional significance of rs3808350 and rs3808351, further studies should3
try to estimate the relationship between rs3808350 and rs3808351 with
cancer in a larger population and other ethnicities to test whether our
findings are statistically robust.
Because rs3808350 and rs3808351 are located in the 50 region of the
GPER gene (rs3808350 (–642) is located in the 50-regulatory region,
while rs3808351 (þ124) is located in the 50-untranslated region and
containing the gene promoter) [10], these polymorphisms may influence
the transcription level of GPER. However, no related studies are currently
available. Since our results showed that GPER expression in cancerous
tissues correlate with the aggressiveness of malignancies and that the A
allele of rs3808351 exhibits protective effects against tumor progression
in the Asian population, it is reasonable to speculate that the G allele of
rs3808351 may be associated with the upregulation of GPER transcrip-
tion. However, only one study has reported the functional role of GPER
polymorphisms in relation to post-transcriptional expression. The study
reported that only rs10235056 was significantly correlated with GPER
mRNA expression [20]. Therefore, further studies are still required to
reveal the exact molecular mechanism underlying our significant
findings.
Although in general we did not find any relationship between
expression level and localization of GPER with cancer progression, other
studies have reported that GPER overexpression is strongly associated
with lower survival rates in several cancer types [43, 54, 55, 59, 60, 62,
63]. Contrastingly, some studies demonstrated that loss of GPER protein
corresponds with low GPER mRNA and poorer prognosis of endometrial
and breast cancer patient [50, 64], possibly due to GPER promoter
hypermethylation [64]. Moreover, it seems that the localization of GPER
in the plasma membrane is responsible for cancer aggressiveness [63].
Thus, in order to evaluate the prognostic value of GPER in cancer pa-
tients, GPER protein level, localization, and promoter hypermethylation
must be examined simultaneously.
Despite being the first meta-analysis in the field, several limitations of
this study should be noted. First, only a limited number of studies were
included for meta-analysis of GPER gene polymorphisms and cancer.
Consequently, further studies are still warranted to test our findings with
a larger sample size. Second, because the etiologies of cancer are com-
plex, other genetic and environmental factors need to be addressed and
may influence the relationship between GPER gene polymorphism, GPER
level, and its localization in different cancer types. Hence, publication
Table 2. Meta-analysis for the association between GPER polymorphisms and cancer.
SNP Genetic model Group No. of studies Test of association Stat. Model Test of heterogeneity Publication bias p-value (Egger's test)
OR 95% CI p-value p-value I2 (%)
rs3808350 G vs. A Overall 5 1.02 [0.72; 1.45] 0.888 Random 0.003 74.50 0.815
Overall* 4 0.91 [0.64; 1.29] 0.604 Random 0.027 67.14 0.943
Asian 3 1.38 [1.06; 1.79] 0.015 Fixed 0.548 0 0.357
Asian* 2 1.22 [0.86; 1.74] 0.252 Fixed 0.595 0 NA
Caucasian 2 0.74 [0.44; 1.24] 0.268 Random 0.025 79.89 NA
GG vs. AG þ AA Overall 5 1.20 [0.59; 2.45] 0.602 Random 0.001 77.16 0.840
Overall* 4 0.99 [0.43; 2.31] 0.996 Random 0.003 77.71 0.837
Asian 3 2.20 [1.42; 3.43] 0.000 Fixed 0.902 0 0.057
Asian* 2 2.11 [1.19; 3.74] 0.010 Fixed 0.700 0 NA
Caucasian 2 0.47 [0.12; 1.81] 0.273 Random 0.036 77.15 NA
GG þ AG vs. AA Overall 5 0.90 [0.71; 1.13] 0.379 Fixed 0.114 46.18 0.584
Overall* 4 0.81 [0.63; 1.05] 0.121 Fixed 0.237 29.12 0.403
Asian 3 1.06 [0.72; 1.57] 0.753 Fixed 0.221 33.66 0.359
Asian* 2 0.79 [0.46; 1.38] 0.424 Fixed 0.342 0 NA
Caucasian 2 0.77 [0.44; 1.34] 0.359 Random 0.068 69.93 NA
GG vs. AA Overall 5 0.95 [0.44; 2.04] 0.913 Random 0.003 74.06 0.583
Overall* 4 0.73 [0.32; 1.68] 0.468 Random 0.021 69.04 0.558
Asian 3 1.83 [1.10; 3.04] 0.019 Fixed 0.355 3.36 0.246
Asian* 2 1.43 [0.72; 2.86] 0.302 Fixed 0.314 1 NA
Caucasian 2 0.42 [0.08; 2.05] 0.287 Random 0.018 82.03 NA
AG vs. AA Overall 5 0.84 [0.65; 1.08] 0.182 Fixed 0.216 30.81 0.132
Overall* 4 0.80 [0.61; 1.05] 0.114 Fixed 0.171 40.05 0.080
Asian 3 0.74 [0.48; 1.15] 0.186 Fixed 0.168 43.81 0.403
Asian* 2 0.51 [0.28; 0.95] 0.033 Fixed 0.396 0 NA
Caucasian 2 0.89 [0.66; 1.21] 0.484 Fixed 0.183 43.50 NA
rs11544331 T vs. C Overall 5 0.91 [0.76; 1.08] 0,299 Fixed 0.204 32.48 0.283
Overall** 3 0.80 [0.63; 1.01] 0,064 Fixed 0.462 0 0.389
TT vs. CT þ CC Overall 4 0.76 [0.49; 1.19] 0,244 Fixed 0.234 29.66 0.662
Overall** 2 0.77 [0.48; 1.24] 0,295 Fixed 0.966 0 0.265
TT þ CT vs. CC Overall 5 0.93 [0.75; 1.16] 0,555 Fixed 0.205 32.41 0.502
Overall** 3 0.76 [0.56; 1.03] 0,080 Fixed 0.398 0 0.543
TT vs. CC Overall 4 0.68 [0.42; 1.09] 0,114 Fixed 0.214 32.91 0.522
Overall** 2 0.66 [0.40; 1.11] 0,122 Fixed 0.748 0 0.723
CT vs. CC Overall 5 0.97 [0.78; 1.22] 0,854 Fixed 0.252 25.31 0.606
Overall** 3 0.78 [0.56; 1.08] 0,136 Fixed 0.418 0 0.532
rs3808351 A vs. G Overall 5 1.07 [0.61; 1.87] 0.809 Random 0.000 89.43 0.657
Overall** 3 0.68 [0.41; 1.12] 0.135 Random 0.032 70.73 0.481
Asian 3 0.83 [0.30; 2.27] 0.716 Random 0.000 90.93 0.732
Asian* 2 0.51 [0.34; 0.75] 0.000 Fixed 0.974 0 NA
Caucasian 2 1.44 [0.65; 3.17] 0.364 Random 0.000 92.33 NA
AA vs. GA þ GG Overall 5 1.27 [0.49; 3.29] 0.618 Random 0.000 82.14 0.817
Overall** 3 0.60 [0.37; 0.97] 0.040 Fixed 0.103 55.95 0.903
Asian 3 1.14 [0.17; 7.38] 0.886 Random 0.000 86.74 0.970
Asian* 2 0.34 [0.14; 0.78] 0.011 Fixed 0.174 45.90 NA
Caucasian 2 1.53 [0.41; 5.71] 0.526 Random 0.007 85.87 NA
AA þ GA vs. GG Overall 5 1.16 [0.56; 2.38] 0.680 Random 0.000 87.44 0.882
Overall** 3 0.66 [0.36; 1.21] 0.182 Random 0.054 65.68 0.219
Asian 3 0.77 [0.26; 2.24] 0.640 Random 0.000 85.67 0.593
Asian* 2 0.48 [0.29; 0.81] 0.006 Fixed 0.571 0 NA
Caucasian 2 1.98 [0.52; 7.50] 0.313 Random 0.000 93.24 NA
AA vs. GG Overall 5 1.56 [0.44; 5.51] 0.484 Random 0.000 88.31 0.798
Overall** 3 0.54 [0.19; 1.57] 0.263 Random 0.069 62.47 0.995
Asian 3 1.12 [0.12; 9.73] 0.916 Random 0.000 89.02 0.988
Asian* 2 0.28 [0.11; 0.69] 0.005 Fixed 0.210 36.18 NA
Caucasian 2 2.42 [0.28; 20.91] 0.419 Random 0.000 93.40 NA
GA vs. GG Overall 5 1.15 [0.61; 2.19] 0.653 Random 0.000 82.10 0.728
(continued on next page)
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Table 2 (continued )
SNP Genetic model Group No. of studies Test of association Stat. Model Test of heterogeneity Publication bias p-value (Egger's test)
OR 95% CI p-value p-value I2 (%)
Overall** 3 0.73 [0.40; 1.32] 0.307 Random 0.081 60.15 0.001
Asian 3 0.78 [0.33; 1.81] 0.564 Random 0.020 74.22 0.402
Asian* 2 0.56 [0.32; 0.98] 0.043 Fixed 0.243 26.59 NA
Caucasian 2 1.93 [0.59; 6.31] 0.271 Random 0.000 90.87 NA
*analysis by excluding Korkmaz et al (2014); **analysis by excluding Korkmaz et al (2014) and Chevalier et al (2014); CI. confidence interval; OR. odds ratio; Stat.
model, statistical model. Bold values indicate statistically significant differences between cases and control, p < 0.05.
Table 3. Characteristics of individual studies and meta-analysis for the association between rs3808350/rs3808351/rs11544331 haplotypes and cancer risk.
No Author (year) Haplotypes Case Control OR (95% CI) [Random] p-value
Events Total Events Total
1 Korkmaz et al (2014) AGC 70 109 87 104 0.55 (0.23–1.34) 0.193
2 Kasap et al (2016) 60 111 45 78
1 Korkmaz et al (2014) AGT 9 109 12 104 1.00 (0.58–1.73) 0.990
2 Kasap et al (2016) 30 111 18 78
1 Korkmaz et al (2014) AAC 25 109 28 104 0.59 (0.29–1.19) 0.143
2 Kasap et al (2016) 11 111 17 78
1 Korkmaz et al (2014) GGC 31 109 34 104 1.87 (0.35–0.89) 0.458
2 Kasap et al (2016) 44 111 10 78
1 Korkmaz et al (2014) GGT 8 109 12 104 0.86 (0.49–1.50) 0.598
2 Kasap et al (2016) 25 111 17 78
1 Korkmaz et al (2014) AAT 11 109 6 104 1.13 (0.50–2.56) 0.755
2 Kasap et al (2016) 14 111 12 78
1 Korkmaz et al (2014) GAC 39 109 20 104 1.64 (0.76–3.54) 0.205
2 Kasap et al (2016) 18 111 12 78
1 Korkmaz et al (2014) GAT 25 109 9 104 1.09 (0.14–8.40) 0.930
2 Kasap et al (2016) 20 111 28 78
CI, confidence interval; OR, odds ratio.
Table 4. Characteristics of individual studies for the association between rs3808351 and tumor size.
No Author (year) Sample size SNP Definition of allele *p HWE Genotype distribution
 T2 < T2 Ref. Alt.  T2 < T2
GG GA AA GG GA AA
1 Chevalier et al (2014) 56 56 rs3808351 G A 0.086 2 9 6 8 32 12
2 Giess et al (2010) 104 246 0.9729 67 30 7 61 64 17
Alt., alternative allele; Ref., reference allele; SNP, Single nucleotide polymorphism. *p for Hardy–Weinberg equilibrium test in controls.
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detailed functional analyses are still needed to uncover the exact mo-
lecular mechanisms of the observed significant association between
GPER and cancer.Table 5. Meta-analysis for the association between rs3808351 and tumor size.
SNP Genetic model No. of studies Test of association
OR 95% CI p-value
rs3808351 A vs. G 2 0.79 [0.29; 2.09] 0.637
AA vs. GA þ GG 2 0.84 [0.40; 1.74] 0.643
AA þ GA vs. GG 2 0.46 [0.28; 0.76] 0.002
AA vs. GG 2 0.53 [0.23; 1.23] 0.142
GA vs. GG 2 0.46 [0.27; 0.79] 0.004
CI, confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism; Stat. m
between  T2 and < T2.
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It is notable that rs3808350 and rs3808351 have the potential to be
used as a prospective biomarker for cancer, with potential use of
rs3808351 in particular as a prognostic marker for cancer progression,
particularly in Asians. Thus, future studies should address the possibilityStat. Model Test of heterogeneity Publication bias p-value (Egger's test)
p-value I2 (%)
Random 0.028 79.25 NA
Fixed 0.107 61.37 NA
Fixed 0.180 44.33 NA
Random 0.111 60.47 NA
Fixed 0.292 9.78 NA
odel, statistical model. Bold values indicate statistically significant differences
Table 6. Characteristics of individual studies for the association between GPER expression levels and cancer progression.
No Author (year) Cancer type Tumor size 2 cm Tumor stage 2 Tumor grade 2
GPERþ/High Total GPER–/Low Total GPERþ/High Total GPER–/Low Total GPERþ/High Total GPER–/Low Total
1 Aiad et al (2014) Breast cancer – – – – – – – – 11 33 6 18
2 Aquino et al (2018)a Salivary Gland Tumors – – – – – – – – 16 26 1 5
Aquino et al (2018)b Salivary Gland Tumors – – – – – – – – 3 4 14 27
3 Friese et al (2017)a Cervical cancer – – – – 96 114 35 42 102 111 38 41
Friese et al (2017)c Cervical cancer – – – – 109 129 22 27 118 125 22 27
4 Heublein (2011)-1 Ovarian Granulosa Cell Tumors – – – – 1 8 2 7 – – – –
Heublein (2011)-2 Ovarian Granulosa Cell Tumors – – – – 1 3 2 12 – – – –
5 Ignatov et al (2011) Breast cancer 84 183 72 140 – – – – 164 182 126 140
6 Ignatov et al (2013) Ovarian cancer – – – – – – – – 85 103 21 21
7 Ignatov et al (2013)** Breast cancer 34 65 39 99 84 99 60 65 – – – –
8 Ignatov et al (2018) Breast cancer 149 352 40 83 – – – – 280 352 74 83
9 Ino et al (2019)* Uterine cervical adenocarcinoma – – – – 9 19 1 34 – – – –
10 Kolkova et al (2012) Ovarian cancer – – – – 36 50 77 100 48 50 95 100
11 Krakstad et al (2012)* Endometrial cancer – – – – – – – – 68 333 79 141
12 Liu et al (2019)a NSCLC – – – – 63 120 8 30 – – – –
Liu et al (2019)b NSCLC – – – – 39 78 32 72 – – – –
13 Luo et al (2011) Breast cancer – – – – – – – – 138 198 10 40
14 Martin et al (2018)a* Breast cancer 124 327 372 910 132 327 351 910 263 327 775 910
Martin et al (2018)b* Breast cancer 111 370 384 864 124 370 348 864 287 370 748 864
15 Samartzis et al (2014)a Breast cancer – – – – 99 189 486 789 136 185 680 781
Samartzis et al (2014)b Breast cancer – – – – 313 528 272 450 443 520 373 446
16 Smith et al (2009)* Ovarian cancer – – – – – – – – 39 52 37 82
17 Steiman et al (2013) Breast cancer – – – – 21 27 14 21 – – – –
18 Tian et al (2018)* Gastric cancer 8 26 18 58 17 26 40 58 4 26 33 58
19 Ye et al (2019)* Breast cancer – – – – 46 74 127 175 62 73 149 176
20 Yu et al (2014) Breast cancer – – – – 48 66 13 30 53 66 23 30
a. cytoplasmic GPER; b. nuclear GPER; c. membrane GPER; *Expression level classified as high/low; **Expression level classified as increase/decrease; 1-Iimunoreactive
score; 2-Intensity.
Table 7. Meta-analysis for the association between GPER expression levels and cancer progression.
Group No. of studies OR (95% CI) [Random] p-value
Tumor size ≥ 2 cm
Overall (GPERþ/–) 2 0.80 (0.58–1.10) 0.168
Overall (GPER high/low) 4 0.88 (0.55–1.39) 0.575
Breast cancer (GPERþ/–) 3 0.87 (0.51–1.46) 0.590
Breast cancer (GPER high/low) 2 0.80 (0.58–1.10) 0.168
Tumor stage ≥ 2
Overall (GPERþ/–) 11 1.18 (0.85–1.64) 0.326
Overall (GPER high/low) 6 0.87 (0.58–1.31 0.497
Asian (GPERþ/–) 3 2.22 (1.12–4.41) 0.022
Asian (GPER high/low) 3 1.65 (0.38–7.21) 0.505
Caucasian (GPERþ/–) 8 0.86 (0.72–1.04) 0.120
Caucasian (GPER high/low) 3 0.85 (0.58–1.20) 0.345
Breast cancer (GPERþ/–) 4 1.15 (0.69–1.92) 0.595
Breast cancer (GPER high/low) 4 0.80 (0.59–1.09) 0.153
Ovarian cancer (GPERþ/–) 3 0.78 (0.38–1.61) 0.505
Tumor grade ≥ 2
Overall (GPERþ/–) 12 1.22 (0.68–2.20) 0.507
Overall (GPER high/low) 5 0.54 (0.25–1.17) 0.117
Caucasian (GPERþ/–) 10 0.94 (0.56–1.60) 0.829
Caucasian (GPER high/low) 4 0.69 (0.31–1.55) 0.368
Breast cancer (GPERþ/–) 5 1.06 (0.44–2.54) 0.894
Ovarian cancer (GPERþ/–) 2 0.49 (0.05–5.12) 0.549
Bold values indicate statistically significant p < 0.05.
Z.S. Ulhaq et al. Heliyon 7 (2021) e06428
6
Z.S. Ulhaq et al. Heliyon 7 (2021) e06428of GPER polymorphisms can be used as an early detection marker for
malignancies in clinical settings. Altogether, our findings indicate that
GPER plays a crucial role in cancer pathogenesis and progression.
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